A great deal of progress has been made in the target therapy for nonsmall cell lung cancer (NSCLC), largely owing to the development of small-molecular inhibitors, such as epidermal growth factor receptor (EGFR) [2–6] and ALK [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.